Hong Kong Eye Hospital, Kowloon, Hong Kong
Department of Ophthalmology and Visual Sciences, Chinese University of Hong Kong, Hong Kong
JAMA Ophthalmol. 2017 Dec 1;135(12):1361-1366. doi: 10.1001/jamaophthalmol.2017.4798.
Endoscopic dacryocystorhinostomy (EN-DCR) is emerging as the preferred procedure in the management of nasolacrimal duct obstructions. However, its safety and long-term efficacy in the setting of acute dacryocystitis with lacrimal sac abscess have not been well studied.
To compare outcomes of EN-DCR as primary treatment with EN-DCR as a secondary treatment after percutaneous drainage of lacrimal sac abscess in acute dacryocystitis.
DESIGN, SETTING, AND PARTICIPANTS: This randomized clinical trial was conducted from October 1, 2012, to October 31, 2015, at a tertiary ophthalmic center. The assessors of success at postoperative year 1 were masked to the procedures received by the participants. All surgical procedures were performed by 2 oculoplastic surgeons with different levels of EN-DCR experience. Eligible participants had acute dacryocystitis and lacrimal sac abscess presenting within 2 weeks of onset, who were 18 to 90 years of age. Analysis was of the intention-to-treat population.
Patients were allocated by block randomization to receive either percutaneous drainage of lacrimal sac abscess followed by EN-DCR after the acute episode subsided (control group) or primary EN-DCR within 2 weeks of presentation (intervention group). Both groups received a course of empirical systemic antibiotics (amoxicillin and clavulanic acid, 375 mg, to be taken 3 times a day for 1 week).
Primary outcomes were time from presentation to documentation of symptom resolution and recurrence within 3 months.
Thirty-two patients were randomized equally into 2 treatment arms (control and intervention). The mean (SD) age of patients was 61 (13) years, and there was a predominance of women (27 [84%]). The mean (SD) time to symptom resolution was 13.8 (5.8) days in the intervention group compared with 31.7 (27.1) days in the control group (mean difference, 17.9; 95% CI, 3.71-32.01; P = .02). The mean (SD) time to surgery in the intervention group was shorter at 11.9 (6.3) days compared with 45.6 (30.1) days in the control group (mean difference, 33.6; 95% CI, 17.92-49.33; P < .001). Recurrences occurred once in the control group and did not occur in the intervention group. No differences in operation time and complications between the 2 groups were identified. The anatomical and functional success was 87.5% (14 of 16 cases) in both groups at postoperative year 1.
Primary EN-DCR in acute dacryocystitis with lacrimal sac abscess results in faster resolution compared with secondary treatment. No differences in recurrence, safety, or outcomes at postoperative year 1 were noted between the 2 treatment groups.
内镜下鼻内泪囊吻合术(EN-DCR)作为治疗鼻泪管阻塞的首选方法正在出现。然而,在急性泪囊炎伴泪囊脓肿的情况下,其安全性和长期疗效尚未得到很好的研究。
比较原发性 EN-DCR 与经皮泪囊脓肿引流后作为继发性 EN-DCR 治疗急性泪囊炎的结果。
设计、地点和参与者:这项随机临床试验于 2012 年 10 月 1 日至 2015 年 10 月 31 日在一家三级眼科中心进行。术后 1 年评估成功的评估者对患者接受的治疗程序不知情。所有手术均由 2 名具有不同 EN-DCR 经验水平的眼整形医生进行。符合条件的参与者患有急性泪囊炎和泪囊脓肿,在发病后 2 周内出现,年龄在 18 至 90 岁之间。分析为意向治疗人群。
患者按块随机分配接受经皮泪囊脓肿引流,然后在急性发作消退后进行 EN-DCR(对照组)或在出现症状后 2 周内进行原发性 EN-DCR(干预组)。两组均接受为期 1 周的经验性全身抗生素治疗(阿莫西林克拉维酸,375mg,每日 3 次)。
主要结果是从出现症状到症状缓解和 3 个月内复发的时间。
32 名患者被随机平均分配到 2 个治疗组(对照组和干预组)。患者的平均(SD)年龄为 61(13)岁,女性居多(27 [84%])。干预组的平均(SD)症状缓解时间为 13.8(5.8)天,对照组为 31.7(27.1)天(平均差异,17.9;95%CI,3.71-32.01;P = .02)。干预组的平均(SD)手术时间较短,为 11.9(6.3)天,而对照组为 45.6(30.1)天(平均差异,33.6;95%CI,17.92-49.33;P < .001)。对照组发生 1 例复发,干预组未发生复发。两组间手术时间和并发症无差异。两组术后 1 年的解剖和功能成功率均为 87.5%(16 例中有 14 例)。
急性泪囊炎伴泪囊脓肿的原发性 EN-DCR 比继发性治疗能更快地缓解症状。两组在术后 1 年的复发率、安全性和结局方面无差异。